Retatrutide vs Mounjaro vs Ozempic: The Honest 2026 Comparison

If you're trying to decide between Ozempic, Mounjaro, and Retatrutide — or just trying to understand why one might be better than another — no fluff, no pharmaceutical marketing. Just the actual differences that matter.

The short version

If you want the headline before the detail:

• Ozempic/Wegovy — works well, widely available on prescription, ~15% weight loss
• Mounjaro — works better, widely available on prescription, ~21–27% weight loss
• Retatrutide — works best, not yet prescription-available in UK, ~28%+ weight loss

If maximum results are your priority and you're willing to self-manage, Retatrutide wins. If you want a fully managed, clinic-prescribed experience, Mounjaro is currently the best option.

Now let's get into why.

How each one works

This is the part most comparison articles skip, and it's the most important thing to understand.

Ozempic / Wegovy (Semaglutide) — single agonist

Semaglutide mimics GLP-1, a hormone your gut naturally releases after eating. GLP-1 signals to your brain that you're full, slows gastric emptying, and helps regulate blood sugar. When you inject semaglutide weekly, you're essentially keeping that "I'm full" signal running constantly.

The result: you eat less, almost without trying. Your appetite changes fundamentally.

Mounjaro (Tirzepatide) — dual agonist

Tirzepatide does everything semaglutide does, and adds GIP (glucose-dependent insulinotropic polypeptide). GIP amplifies the GLP-1 effect and improves how your body handles insulin. The combination is more potent — hence the better results.

Think of it as Ozempic with the volume turned up.

Retatrutide — triple agonist

Retatrutide adds a third target: glucagon receptors. This is the leap that separates it from the others.

Glucagon is a hormone that directly increases energy expenditure — your body burns more calories at rest. It also specifically targets visceral fat (the fat stored around your organs, associated with the highest health risks). No existing approved drug does this.

The result of hitting all three receptors simultaneously:

• Appetite suppressed (GLP-1)
• Insulin sensitivity improved (GIP)
• Metabolism actively accelerated (glucagon)

It's not just "more of the same" — it's a genuinely different mechanism layered on top.

Weight loss: the numbers

This is what most people actually want to know.

These numbers come from clinical trials, not anecdotes. The gap between Ozempic and Retatrutide is not marginal. At 100kg starting weight, we're talking about the difference between losing 15kg or losing 28kg.

That's a different body.

Side effects: how do they compare?

All three share a similar side effect profile because they all work on the GLP-1 pathway. The differences are in intensity.

The pattern: the more powerful the drug, the more pronounced the early side effects. Retatrutide hits hardest in the first month. Most people find this manageable if they start low and titrate slowly — those who rush the dose increase tend to have a rough time.

By weeks 6–8, the nausea has usually settled considerably for all three drugs. The appetite suppression — the useful part — remains.

One important note for Retatrutide: the glucagon component can cause more significant nausea than the other two, particularly if you eat fatty or heavy foods. A lighter diet during the titration phase makes a meaningful difference.

Cost: the real numbers (UK, 2026)

This is where things get interesting.

The research peptide route is dramatically cheaper for all three — but it comes with more responsibility. You're reconstituting vials, managing your own dosing, and operating without medical oversight.

Retatrutide is only available via the research peptide route in the UK right now. There is no clinic, no Turkish pharmacy, no prescription option. If you want it before MHRA approval (expected 2026–2027, NHS availability 2028+), you're sourcing it yourself.

Availability in the UK

Which one should you choose?

Choose Ozempic/Wegovy if…

• You want the most studied, longest-track-record option
• You prefer the NHS or a standard private clinic route
• 15% weight loss meets your goal
• You're needle-averse and want the most established self-injector pen

Choose Mounjaro if…

• You want the best results available on prescription right now
• You prefer full medical oversight
• You don't want to self-manage reconstitution
• ~21–27% weight loss is your target

Choose Retatrutide if…

• You want maximum results (28%+)
• You're comfortable self-managing the research peptide process
• Cost is a factor — the research route is far cheaper
• You've already tried Mounjaro or Ozempic and want to step up
• You're willing to start low and titrate slowly through the initial side effects

The honest takeaway

I tried to approach this decision the way I'd approach any significant financial or health decision: look at the data, understand the tradeoffs, and make a rational choice.

The data says Retatrutide is more effective than either alternative. The tradeoff is that it requires more self-management and isn't available on prescription in the UK yet. For me, that tradeoff was worth it. For someone who wants the simplest, most supported experience, Mounjaro via a private clinic is the right answer.

Neither is wrong. They're different choices for different people.

What I'd push back on is defaulting to Ozempic simply because it's the most famous. If you're going to commit to a weekly injection programme, it's worth understanding what the alternatives offer — and whether the extra step of Retatrutide's self-managed route is worth the significantly better results.

For me, it was.